Key Points
- CTO Seshu Tyagarajan sold 7,000 Candel Therapeutics shares at an average price of $12, generating $84,000 and reducing his direct stake by 8.35% to 76,865 shares.
- Candel shares opened at $13.50, near their 52-week high of $13.82, with a market capitalization of approximately $1.03 billion. The company recently reported a quarterly loss of $0.52 per share, missing analyst expectations by $0.28.
- Analyst sentiment remains a Moderate Buy, with a consensus price target of $19.29, although ratings range from Sell to Buy. Institutional investors own about 13.93% of the company.
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) CTO Seshu Tyagarajan sold 7,000 shares of Candel Therapeutics stock in a transaction on Monday, August 17th. The shares were sold at an average price of $12.00, for a total value of $84,000.00. Following the sale, the chief technology officer directly owned 76,865 shares of the company's stock, valued at approximately $922,380. The trade was a 8.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Seshu Tyagarajan also recently made the following trade(s):
- On Monday, June 29th, Seshu Tyagarajan sold 7,000 shares of Candel Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $70,140.00.
Candel Therapeutics Stock Up 12.0%
Candel Therapeutics stock opened at $13.50 on Thursday. The company has a current ratio of 16.09, a quick ratio of 16.09 and a debt-to-equity ratio of 0.38. Candel Therapeutics, Inc. has a 1-year low of $4.35 and a 1-year high of $13.82. The firm's fifty day simple moving average is $9.93 and its 200-day simple moving average is $7.55. The company has a market capitalization of $1.03 billion, a P/E ratio of -9.57 and a beta of -0.51.
Candel Therapeutics (NASDAQ:CADL - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.28). Sell-side analysts forecast that Candel Therapeutics, Inc. will post -1.3 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Candel Therapeutics in a research report on Friday, July 17th. Wall Street Zen cut Candel Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday. HC Wainwright reiterated a "buy" rating and issued a $23.00 price objective on shares of Candel Therapeutics in a research report on Thursday, August 13th. Stifel Nicolaus initiated coverage on Candel Therapeutics in a report on Monday, July 13th. They set a "buy" rating and a $22.00 price objective on the stock. Finally, Bank of America boosted their price objective on Candel Therapeutics from $9.00 to $12.00 and gave the company a "neutral" rating in a research report on Friday, August 14th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $19.29.
View Our Latest Research Report on Candel Therapeutics
Hedge Funds Weigh In On Candel Therapeutics
Institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets raised its holdings in shares of Candel Therapeutics by 128.2% in the third quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company's stock valued at $40,000 after buying an additional 4,439 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Candel Therapeutics by 361.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company's stock valued at $49,000 after acquiring an additional 7,527 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Candel Therapeutics in the fourth quarter worth about $51,000. ProShare Advisors LLC bought a new stake in shares of Candel Therapeutics during the fourth quarter valued at approximately $59,000. Finally, Invesco Ltd. bought a new stake in shares of Candel Therapeutics during the first quarter valued at approximately $59,000. Institutional investors own 13.93% of the company's stock.
About Candel Therapeutics
(
Get Free Report)
Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company's lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.
In addition to its lead program, Candel's pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
